Acura Pharmaceuticals Announces Return of Product Rights

Acura Pharmaceuticals Announces Return of Product Rights 
PALATINE, IL -- (Marketwired) -- 04/10/14 --  Acura Pharmaceuticals,
Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing
products intended to address medication abuse and misuse, announced
today a letter agreement with Pfizer Inc. providing for the
termination of Pfizer's license to Acura's AVERSION(R) Technology and
the return to Acura of the FDA approved Oxecta(R) (oxycodone HCl)
product. The letter agreement provides that Acura will make a
one-time payment of $2.0 million to Pfizer. The license termination
is effective April 9, 2014. The AVERSION(R) Technology utilizes a
proprietary mixture of inactive ingredients to discourage tampering
of a product for abusive purposes. 
"We are pleased that we have been able to reach agreement on
acceptable terms for the license termination," said Bob Jones,
President and Chief Executive Officer of Acura Pharmaceuticals. Mr.
Jones further added, "We are currently evaluating our strategic
options for the returned product and our other AVERSION(R) Technology
products in development, which may include a re-launch under a new
brand name in partnership with another pharmaceutical company."  
The Company will host a conference call to discuss our strategies for
the product going forward on Friday, April 11, 2014 at 8:30 am ET. To
participate in the live conference call, please dial 1-888-556-4997
(U.S. and Canada) five to ten minutes prior to the start of the call.
The participant passcode is 9666652 
About Acura Pharmaceuticals
 Acura Pharmaceuticals is a specialty
pharmaceutical company engaged in the research, development and
commercialization of product candidates intended to address
medication abuse and misuse, utilizing its proprietary AVERSION(R)
and IMPEDE(R) Technologies. AVERSION(R) contains polymers that cause
the drug to gel when dissolved; it also contains compounds that
irritate the nasal passages. IMPEDE(R) is designed to disrupt the
processing of pseudoephedrine from tablets into methamphetamine. 
In June 2011, the U.S. Food and Drug Administration approved
OXECTA(R) (oxycodone HC1 tablets) which incorporates the AVERSION(R)
technology. The Company has a development pipeline of additional
AVERSION(R) technology products containing other opioids.  
Forward-Looking Statements  
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause our
actual results, performance or achievements to be materially
different from any future results, performance, or achievements
expressed or implied by such forward-looking statements.
Forward-looking statements may include, but are not limited to, our
ability to enter into a license agreement for our Aversion oxycodone
product, our and our licensee's ability to successfully launch and
commercialize our products and technologies including our Aversion
oxycodone and NEXAFED(R) Tablets, the price discounting that may be
offered by our licensee for Aversion oxycodone, our or our licensee's
ability to obtain commercial supplies of Aversion oxycodone from a
third party contract manufacturer, our and our licensee's ability to
obtain necessary regulatory approvals and commercialize products
utilizing our technologies and the market acceptance of and
competitive environment for any of our products, the willingness of
wholesalers and pharmacies to stock NEXAFED(R) Tablets, expectations
regarding the terms and payments under any license agreement for our
products, expectations regarding potential market share for our
products and the timing of first sales, our ability to enter into
additional license agreements for our AVERSION(R) Technology product
candidates, our exposure to product liability and other lawsuits in
connection with the commercialization of our products, the increasing
cost of insurance and the availability of product liability insurance
coverage, the ability to avoid infringement of patents, trademarks
and other proprietary rights of third parties, and the ability of our
patents to protect our products from generic competition, our ability
to protect and enforce our patent rights in any paragraph IV patent
infringement litigation, and the ability to fulfill the FDA
requirements for approving our product candidates for commercial
manufacturing and distribution in the United States, including,
without limitation, the adequacy of the results of the laboratory and
clinical studies completed to date, the results of laboratory and
clinical studies we may complete in the future to support FDA
approval of our product candidates and the sufficiency of our
development to meet OTC Monograph standards as applicable, the
adequacy of the development program for our product candidates,
including whether additional clinical studies will be required to
support FDA approval of our product candidates, changes in regulatory
requirements, adverse safety findings relating to our product
candidates, whether the FDA will agree with our analysis of our
clinical and laboratory studies and how it may evaluate the results
of these studies or whether further studies of our product candidates
will be required to support FDA approval, whether or when we are able
to obtain FDA approval of labeling for our product candidates for the
proposed indications and will be able to promote the features of our
abuse discouraging technologies, whether our product candidates will
ultimately deter abuse in commercial settings and whether our Impede
technology will disrupt the processing of pseudoephedrine into
methamphetamine. In some cases, you can identify forward-looking
statements by terms such as "may," "will," "should," "could,"
"would," "expects," "plans," "anticipates," "believes," "indicates,"
"estimates," "projects," "predicts," "potential" and similar
expressions intended to identify forward-looking statements. These
statements reflect our current views with respect to future events
and are based on assumptions and subject to risks and uncertainties.
Given these uncertainties, you should not place undue reliance on
these forward-looking statements. We discuss many of these risks in
greater detail in our filings with the Securities and Exchange
for Acura Investor Relations 
for Acura Media Relations 
Press spacebar to pause and continue. Press esc to stop.